Contact
Bone Therapeutics

Our History

2016

  • Thomas Lienard appointed Chief Executive Officer
  • Bone Therapeutics shortlisted for two prestigious awards: Scrip Awards - Quintiles’ Clinical Advance of the Year and European Small and Mid-Cap Awards - Star of Innovation
  • Bone Therapeutics reports positive efficacy data for the ALLOB® Phase IIA spinal fusion trial
  • Bone Therapeutics demonstrates superiority of PREOB® in Phase IIB osteonecrosis study presented at EULAR
  • Bone Therapeutics celebrates ten years of innovation in bone cell therapy
  • Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development
  • Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial
  • Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study
  • Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis
  • Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial
  • Bone Therapeutics extends Kasios collaboration
  • Bone Therapeutics expands its delayed-union program with ALLOB® into multiple fractures

2015

  • Bone Therapeutics treats first patients in pioneering trial for minimally invasive treatment of failed spinal fusion
  • Bone Therapeutics treats second patient cohort in ALLOB ®  Phase I/IIA delayed-union fracture trial
  • Bone Therapeutics reports first results of its Phase IIA trial for PREOB ® in severe osteoporosis
  • Bone Therapeutics officially opens its new headquarters in Gosselies
  • Bone Therapeutics establishes US subsidiary
  • Bone Therapeutics treats first patients in ALLOB ® Phase IIA spinal fusion trial
  • Bone Therapeutics accelerates its ALLOB ® Phase I/IIA delayed-union trial
  • Bone Therapeutics raises EUR32.2M in 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris
  • Bone Therapeutics demonstrates efficacy in first patient cohort in ALLOB ® Phase I/IIA delayed-union trial
  • Bone Therapeutics expands product portfolio with new research into innovative combined cell-matrix product

2014

  • Bone Therapeutics confirms safety in ALLOB ® Phase I/IIa trial for delayed-union fractures
  • Guy Heynen appointed as Chief Clinical and Regulatory Officer of the Company
  • Bone Therapeutics and Kasios collaborate on novel product for spinal fusion
  • The Company and partners awarded prestigious M-ERA.net research funding
  • Renewal of Certificate of GMP Compliance
  • Clearance to start ALLOB ® Phase IIa trial for in spinal fusion procedures for degenerative lumbar disc disease
  • ALLOB ® granted ODD status for osteonecrosis in the US
  • First patient treated with ALLOB®
  • ALLOB ® patent granted in JP & AU
  • IRD patent granted in JP & AU

2013

  • Wim Goemaere appointed Chief Financial Officer of the Company
  • €3.8 million Marie Curie research grant awarded to the Company and partners
  • Approval of ALLOB ® Phase I/II trial in delayed-union fractures
  • ALLOB ® granted ODD status for osteonecrosis in Europe
  • Start of Phase IIa osteoporosis trial for PREOB®
  • PREOB ® patent granted in JP & US
  • ALLOB ® Tissue bank/Intermediary Structure license & manufacturing authorization for Europe
  • €6 million raised in an equity financing round

2012

  • Establishment of the Walloon Cell Therapy Platform (PWTC): infrastructure for clinical trials and commercial production of cell therapy products
  • Clearance to start PREOB® Phase IIb/III trial for the treatment of non-union fractures
  • Approval of PREOB ® Phase III osteonecrosis trial in Europe and treatment of first patients
  • IRD patent granted in Europe

2011

  • Tissue Production Establishment license
  • ALLOB® classified as Tissue Engineered Product (non-combined) under ATMP classification 1394/2007EMA
  • €6.6 million raised in an equity financing round

2010

  • Certificate of GMP Compliance granted

2009

  • Initiation of the allogeneic osteoblastic program ALLOB®

2008

  • PREOB® for osteonecrosis granted ODD status in the US
  • €4.5 million raised in an equity financing round

2007

  • PREOB® for osteonecrosis granted ODD status in Europe
  • PREOB® classified as Pharmaceutical Product by the European Medicines Agency
  • Initiation of operations
  • €0.9 million raised in seed financing

2006

  • Founded as a spin-off from the Université libre de Bruxelles (Brussels, Belgium)